These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30018134)

  • 1. Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.
    Jung KH; Ataseven B; Verrill M; Pivot X; De Laurentiis M; Al-Sakaff N; Lauer S; Shing M; Gligorov J; Azim HA
    Oncologist; 2018 Oct; 23(10):1137-1143. PubMed ID: 30018134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
    Gligorov J; Ataseven B; Verrill M; De Laurentiis M; Jung KH; Azim HA; Al-Sakaff N; Lauer S; Shing M; Pivot X;
    Eur J Cancer; 2017 Sep; 82():237-246. PubMed ID: 28625777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.
    Gligorov J; Pivot X; Ataseven B; De Laurentiis M; Jung KH; Manikhas A; Abdel Azim H; Gupta K; Alexandrou A; Herraez-Baranda L; Tosti N; Restuccia E
    Breast; 2022 Aug; 64():151-158. PubMed ID: 35487845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
    Zambetti M; Montemurro F; Morandi P; Zamagni C; Brandes AA; Bisagni G; Cagossi K; Bengala C; Gori S; Iannacone C; Stell A; Gianni L
    Eur J Cancer; 2018 Dec; 105():61-70. PubMed ID: 30396014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
    Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
    Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
    Cameron D; Piccart-Gebhart MJ; Gelber RD; Procter M; Goldhirsch A; de Azambuja E; Castro G; Untch M; Smith I; Gianni L; Baselga J; Al-Sakaff N; Lauer S; McFadden E; Leyland-Jones B; Bell R; Dowsett M; Jackisch C;
    Lancet; 2017 Mar; 389(10075):1195-1205. PubMed ID: 28215665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.
    Papakonstantinou A; Matikas A; Bengtsson NO; Malmström P; Hedayati E; Steger G; Untch M; Hübbert L; Johansson H; Hellström M; Gnant M; Loibl S; Greil R; Moebus V; Foukakis T; Bergh J
    Cancer; 2020 Mar; 126(6):1175-1182. PubMed ID: 31851385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
    Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
    Kirschbrown WP; Wynne C; Kågedal M; Wada R; Li H; Wang B; Nijem I; Badovinac Crnjevic T; Gasser H; Heeson S; Eng-Wong J; Garg A
    J Clin Pharmacol; 2019 May; 59(5):702-716. PubMed ID: 30570763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
    Earl HM; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Harnett AN; Ah-See ML; Simcock R; Rea D; Raj S; Woodings P; Harries M; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mansi J; Gounaris I; Mahler-Araujo B; Provenzano E; Chhabra A; Abraham JE; Caldas C; Hall PS; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA;
    Lancet; 2019 Jun; 393(10191):2599-2612. PubMed ID: 31178152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial.
    Jackisch C; Stroyakovskiy D; Pivot X; Ahn JS; Melichar B; Chen SC; Meyenberg C; Al-Sakaff N; Heinzmann D; Hegg R
    JAMA Oncol; 2019 May; 5(5):e190339. PubMed ID: 30998824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
    von Minckwitz G; Huang CS; Mano MS; Loibl S; Mamounas EP; Untch M; Wolmark N; Rastogi P; Schneeweiss A; Redondo A; Fischer HH; Jacot W; Conlin AK; Arce-Salinas C; Wapnir IL; Jackisch C; DiGiovanna MP; Fasching PA; Crown JP; Wülfing P; Shao Z; Rota Caremoli E; Wu H; Lam LH; Tesarowski D; Smitt M; Douthwaite H; Singel SM; Geyer CE;
    N Engl J Med; 2019 Feb; 380(7):617-628. PubMed ID: 30516102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab/Hyaluronidase-oysk: A New Option for Patients With HER2-Positive Breast Cancer.
    Duco MR; Murdock JL; Reeves DJ
    Ann Pharmacother; 2020 Mar; 54(3):254-261. PubMed ID: 31595774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin
    Schmidt M; KÜmmel S; Ruf-Doerdelmann A; Distelrath A; Wacker J; Schmatloch S; Busch-Liles S; LÜdtke-Heckenkamp K
    Anticancer Res; 2021 Jan; 41(1):485-496. PubMed ID: 33419847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study.
    Jacquin JP; Uwer L; Savignoni A; Ferrero JM; Lortholary A; Solub D; Delaporte F; Chalabi N; Pibre S; Belkacemi Y
    Breast; 2020 Feb; 49():1-7. PubMed ID: 31670262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.